EGFR

[Cancer Immunology Immunotherapy] In an in vitro study using lung cancer cell lines and human monocyte-derived macrophages, the conditioned medium from cancer cells was found to up-regulate programmed cell death-1 ligand 1 expression on macrophages via STAT3 activation.

[Science Translational Medicine] Scientists performed the basal-like breast cancers (BLBCs) tissue microarray–based immunohistochemical analysis and showed that Faciogenital Dysplasia 5 abundance was associated with poor prognosis in BLBCs.

[Cell Death & Disease] Scientists detected the receptor tyrosine kinase activity in gefitinib-resistant colorectal cancer cells, pan-erb-b2 receptor tyrosine kinase 3 (ErbB3)/EGFR was significantly activated and provided a potential multi-ErbB treatment target.

[Toxicology and Applied Pharmacology] Investigators modified sets of lipids conjugated with cell-penetrating TAT peptide, MMP2 enzyme-sensitive moiety, and cetuximab antibodies against the EGF receptor were synthesized, purified and verified on HPLC, TLC, SEM, and DLS analyses.

[Immunologic Research] In this current study, the authors discovered that epidermal growth factor receptor affected major histocompatibility complex class I mRNA and protein expression by human pancreatic cancer cell lines.

[Experimental Dermatology] The authors showed that protein phosphatase 2 A catalytic subunit α isoform (PP2Acα) negatively regulated epidermal growth factor receptor (EGFR) phosphorylation and epidermal cell proliferation, and EGFR inhibitors potentially alleviated PP2Acα by inhibiting epidermal cell proliferation.